ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 1
Introduction to CAR T-Cell Therapies in R/R ALL
Panelists discuss how the recent FDA approval of obecabtagene autoleucel (obe-cel) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) adds to the existing chimeric antigen receptor (CAR) T-cell therapies, with a focus on the differences in their mechanisms, structures, and FDA indications.
Video content above is prompted by the following:
- We recently had a third CAR T-cell therapy, obe-cel, approved for R/R ALL. Could you introduce the 3 CAR T-cell therapies that are currently available, including their FDA indications, general mechanisms of action, and differences in structure?
Related Content:
